HomeCompareVACC vs PLD

VACC vs PLD: Dividend Comparison 2026

VACC yields 40.00% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.68M in total portfolio value· pulled ahead in Year 7
10 years
VACC
VACC
● Live price
40.00%
Share price
$5.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$231.9K
Annual income
$39,181.04
Full VACC calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — VACC vs PLD

📍 PLD pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVACCPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VACC + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VACC pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VACC
Annual income on $10K today (after 15% tax)
$3,400.00/yr
After 10yr DRIP, annual income (after tax)
$33,303.88/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $4,004,812.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VACC + PLD for your $10,000?

VACC: 50%PLD: 50%
100% PLD50/50100% VACC
Portfolio after 10yr
$3.07M
Annual income
$2,394,953.11/yr
Blended yield
78.01%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

VACC
Analyst Ratings
3
Buy
1
Hold
Consensus: Buy
Altman Z
0.8
Piotroski
2/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VACC buys
0
PLD buys
0
No recent congressional trades found for VACC or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVACCPLD
Forward yield40.00%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$231.9K$5.91M
Annual income after 10y$39,181.04$4,750,725.19
Total dividends collected$174.4K$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: VACC vs PLD ($10,000, DRIP)

YearVACC PortfolioVACC Income/yrPLD PortfolioPLD Income/yrGap
1$14,700$4,000.00$11,241$540.96+$3.5KVACC
2$21,224$5,495.33$13,019$991.13+$8.2KVACC
3$30,125$7,415.26$15,801$1,870.97+$14.3KVACC
4$42,071$9,836.48$20,609$3,701.21+$21.5KVACC
5$57,854$12,838.17$29,919$7,867.97+$27.9KVACC
6$78,403$16,499.54$50,631$18,617.74+$27.8KVACC
7← crossover$104,788$20,897.28$105,528$51,352.20$740.00PLD
8$138,226$26,102.79$287,364$174,449.42$149.1KPLD
9$180,082$32,179.61$1,081,760$774,280.77$901.7KPLD
10$231,869$39,181.04$5,908,209$4,750,725.19$5.68MPLD

VACC vs PLD: Complete Analysis 2026

VACCStock

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

Full VACC Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this VACC vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VACC vs SCHDVACC vs JEPIVACC vs OVACC vs KOVACC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.